Holen Sie sich die Stockscreener-App
20.10
0.70%
0.14
Handel nachbörslich:
20.10
Schlusskurs vom Vortag:
$19.96
Offen:
$20.02
24-Stunden-Volumen:
1.59M
Relative Volume:
1.07
Marktkapitalisierung:
$1.78B
Einnahmen:
$172.60M
Nettoeinkommen (Verlust:
$-285.42M
KGV:
-6.0977
EPS:
-3.2963
Netto-Cashflow:
$-323.17M
1W Leistung:
-4.78%
1M Leistung:
-20.08%
6M Leistung:
+33.11%
1J Leistung:
+48.12%
1-Tages-Spanne:
$19.45
$20.15
1-Wochen-Bereich:
$19.00
$21.55
52-Wochen-Spanne:
$8.58
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Firmenname
Syndax Pharmaceuticals Inc
Sektor
Branche
Telefon
781-419-1400
Adresse
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
20.10 | 1.77B | 172.60M | -285.42M | -323.17M | -3.2963 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-09-10 | Fortgesetzt | Stifel | Buy |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-10-25 | Eingeleitet | BofA Securities | Buy |
| 2023-10-11 | Eingeleitet | Goldman | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-11 | Eingeleitet | Guggenheim | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2023-01-03 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-04-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-15 | Eingeleitet | Goldman | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-25 | Eingeleitet | Citigroup | Buy |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-05-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Eingeleitet | FBR & Co. | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-10-07 | Eingeleitet | Guggenheim | Buy |
| 2016-03-28 | Eingeleitet | Citigroup | Buy |
| 2016-03-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-03-28 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Syndax Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-05-05 - Seeking Alpha
HC Wainwright Has Optimistic Outlook of SNDX Q2 Earnings - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - simplywall.st
(SNDX) Risk Channels and Responsive Allocation - Stock Traders Daily
Biotech Momentum Builds As Syndax Pharmaceuticals Draws Market Attention - Kalkine Media
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% Following Analyst Upgrade - MarketBeat
Stifel raises Syndax Pharmaceuticals stock price target on therapy outlook By Investing.com - Investing.com Canada
Stifel raises Syndax Pharmaceuticals stock price target on therapy outlook - Investing.com
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Released Its First-Quarter Earnings: Here's What Analysts Think - 富途牛牛
HC Wainwright Has Optimistic Outlook of SNDX FY2030 Earnings - MarketBeat
MSN Money - MSN
Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives - Sahm
Net current asset value per share of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView
Syndax Pharmaceuticals Q1 Loss Narrows, Revenue Rises - Moomoo
Syndax Pharmaceuticals Reports Over $100 Million in Q1 Combined Sales - HarianBasis.co
Jefferies Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
Syndax Pharmaceuticals 1Q Loss $42.7M >SNDX - Moomoo
Syndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain TractionWhat’s Really Shifting? - Yahoo Finance
Syndax Pharmaceuticals Inc ($SNDX) CEO 2025 Pay Revealed - Quiver Quantitative
Stifel raises Syndax Pharmaceuticals stock price target on therapy trajectory By Investing.com - Investing.com Canada
Jefferies cuts Syndax Pharmaceuticals price target on transplant impact By Investing.com - Investing.com Canada
SNDX Maintained by Barclays -- Price Target Raised to $37 - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 7.1%Time to Sell? - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $37.00 - MarketBeat
Syndax Pharmaceuticals stock price target raised to $29 by BofA - Investing.com Australia
Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highligh - GuruFocus
SNDX SWOT Analysis: Financial Resilience Amidst Clinical Development Challenges Revealed in 10-Q Filing - GuruFocus
Earnings Call Summary | Syndax Pharmaceuticals(SNDX.US) Q1 2026 Earnings Conference - Moomoo
Syndax Pharmaceuticals (SNDX) Reports Strong Q1 2026 Earnings an - GuruFocus
Syndax Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Quarterly Earnings Results - MarketBeat
SNDX Sees Strong Demand Despite Q1 Revenue Miss - GuruFocus
How Should Investors Value Syndax Pharmaceuticals (SNDX) After Q - GuruFocus
Earnings call transcript: Syndax Pharmaceuticals beats Q1 2026 EPS expectations - Investing.com
Earnings Flash (SNDX) Syndax Pharmaceuticals Posts Q1 Loss $0.48, vs. FactSet Est of $0.61 Loss - marketscreener.com
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Syndax (NASDAQ: SNDX) details 2026 virtual meeting, director votes and 7.2M-share plan - Stock Titan
Q1 2026 Syndax Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
SNDX: Revenue up 224% to $64.9M; net loss halved; strong growth in Revuforj and Niktimvo sales - TradingView
Syndax: Q1 Earnings Snapshot - KVUE
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Earnings Flash (SNDX) Syndax Pharmaceuticals, Inc. Reports Q1 Revenue $64.9M, vs. FactSet Est of $69.8M - marketscreener.com
Syndax Pharmaceuticals | 10-Q: Q1 2026 Earnings Report - Moomoo
Syndax Pharmaceuticals Sees 2026 Total R&D Plus SG&A Expenses Approximately $400 M>SNDX - Moomoo
Cancer drug sales top $100M as Syndax lines up late-2026 trial data - Stock Titan
Syndax (NASDAQ: SNDX) triples revenue as Revuforj and Niktimvo ramp - Stock Titan
Syndax Pharmaceuticals | 8-K: Syndax Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Syndax (NASDAQ: SNDX) posts 224% Q1 revenue surge and lower loss - Stock Titan
Vanguard Capital Management holds 4.46M shares in Syndax (SNDX) - Stock Titan
Syndax Pharmaceuticals earnings face test as competition heats up By Investing.com - Investing.com India
Syndax Pharmaceuticals earnings face test as competition heats up - Investing.com UK
Finanzdaten der Syndax Pharmaceuticals Inc-Aktie (SNDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):